Xeris Biopharma Holdings, Inc. (XERS) Reports Record $71.5M Q2 Revenue

We recently published 10 Best Biotech Stocks to Buy Under $10. Xeris Biopharma Holdings, Inc. is placed among them.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a Chicago-based commercial-stage biopharmaceutical company focused on therapies for chronic endocrine and neurological diseases. Its key products include Recorlev for Cushing’s syndrome, Gvoke for severe hypoglycemia, and Keveyis for primary periodic paralysis, with a promising pipeline candidate, XP-8121, in Phase 3 for hypothyroidism.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) reported record Q2 2025 revenue of $71.5 million, a 49% year-over-year increase, with Recorlev sales surging 136%. This strong performance prompted the company to raise its 2025 revenue guidance to $280–$290 million.

In June 2025, the business held its first Analyst and Investor Day, presenting a long-term growth vision targeting $750 million total revenue by 2030 and $1–$3 billion peak net revenue from XP-8121 by 2035. The company is expanding its commercial infrastructure while investing in pipeline innovation, signaling confidence in sustaining growth through existing therapies and future product launches.

While Recorlev drives immediate revenue growth, XP-8121 offers potential diversification and long-term revenue expansion. The dual focus on commercial execution and clinical advancement positions Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) as a competitive player in the biotech sector, with transformative potential in endocrine disease treatment.

While we acknowledge the potential of XERS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.